NEW YORK (GenomeWeb) – Sialix said this week that it has raised an additional $2 million as part of its Series B round, bringing the total raised to $6 million.
The company also said that it has changed its name to Siamab Therapeutics, marking its shift from a glycomics-focused firm to one focused on developing therapeutic antibodies for cancer.
GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
You may already have institutional access!
Already a GenomeWeb or 360Dx Premium member?
Login Now.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
